Veru (NASDAQ:VERU) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Veru (NASDAQ:VERU) announced its earnings results on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.15, Zacks reports. The business had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $1.90 million.

Here are the key takeaways from Veru’s conference call:

• Veru highlighted positive Phase 2b QUALITY data for enobosarm plus semaglutide, saying it preserved lean mass and reduced the proportion of patients with a clinically significant decline in stair climb power versus semaglutide alone.
• The company said the 3 mg enobosarm arm produced a statistically significant 59.8% relative reduction in patients with at least a 10% decline in stair climb power, while the 6 mg arm showed a 44.1% relative reduction.
• Veru is now running the Phase 2b plateau study in older adults with obesity to test whether enobosarm can help patients break through the common GLP-1 weight-loss plateau and generate incremental weight loss while preserving function and bone health.
• Management said the first interim analysis for the plateau study is expected in Q1 calendar 2027, and that enrollment is progressing well and remains on track.
• Financially, Veru ended the quarter with $27.6 million in cash and restricted cash, and management said this should fund operations beyond the interim analysis. The quarterly net loss from continuing operations also improved to $3.1 million from $7.9 million a year ago.

Veru Price Performance

Veru stock traded down $0.17 during midday trading on Thursday, reaching $2.09. The company’s stock had a trading volume of 192,819 shares, compared to its average volume of 77,762. The stock has a market capitalization of $33.54 million, a P/E ratio of -1.66 and a beta of -1.19. The stock’s 50-day simple moving average is $2.35 and its 200-day simple moving average is $2.46. Veru has a 52-week low of $2.05 and a 52-week high of $7.40.

Hedge Funds Weigh In On Veru

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its holdings in shares of Veru by 388.7% during the fourth quarter. NewEdge Advisors LLC now owns 70,525 shares of the company’s stock worth $151,000 after purchasing an additional 56,095 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Veru during the 4th quarter valued at approximately $75,000. Blair William & Co. IL grew its position in Veru by 26.3% during the fourth quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock valued at $103,000 after buying an additional 10,000 shares during the period. Alyeska Investment Group L.P. acquired a new stake in Veru in the fourth quarter valued at approximately $2,140,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Veru in the 3rd quarter valued at about $110,000. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Key Stories Impacting Veru

Here are the key news stories impacting Veru this week:

• Positive Sentiment: Veru beat earnings expectations for fiscal Q2 2026, reporting a loss of $0.13 per share versus consensus for a $0.28 loss. The company also said enrollment is actively underway in its Phase 2b PLATEAU obesity study, with an interim readout still expected in Q1 2027. Article Title
• Positive Sentiment: Management highlighted improving cost discipline, with R&D and G&A expenses both down year over year, operating losses narrowing, and cash/cash equivalents rising to $27.6 million from $15.8 million at the prior fiscal year-end. Article Title
• Neutral Sentiment: Several earnings-call writeups and transcripts reiterated the same core message: the stock’s near-term story is being driven by the PLATEAU program, which is testing enobosarm plus semaglutide for weight loss and preservation of lean mass. Article Title
• Neutral Sentiment: Canaccord Genuity kept a Q2 EPS estimate of a $0.20 loss, suggesting analysts still expect Veru to remain unprofitable this year despite the quarter’s smaller-than-expected loss. Article Title
• Negative Sentiment: Revenue was far below expectations at just $0.06 million versus $1.90 million expected, underscoring that Veru is still a development-stage biotech with limited commercial sales. Article Title
• Negative Sentiment: The stock still depends heavily on future clinical data, and any delay or weak result in the PLATEAU trial could hurt sentiment, especially since top-line data is not expected until late 2027. Article Title

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Veru in a research report on Monday, April 20th. Wall Street Zen cut Veru from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.